--- title: Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial description: Simsen Diagnostics, a leader in ultrasensitive analysis of nucleic acids, today announced a collaboration with One-carbon Pharmaceuticals, a Swedish pharmaceutical company, for their groundbreaking ODIN trial. This first-in-human, first-in-class Phase 1/2 clinical trial will evaluate TH9619, a novel MTHFD1/2 inhibitor, in patients with selected solid cancers. image: https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%20laboratory%20setting%20filled%20with%20advanced%20equipment%20and%20technology.jpeg --- [Skip to the main content.](https://simsendiagnostics.com/news/simsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLq3ExJ1vvVZLqTYQKUKszzECna8UfNJMyWftlkE5q0N7yQ5muraa43pMDOGoPsNz8F3s0s3iWPLTXB636a9l9ssA4ZYjuJMlTE6Nl0fQsAp596tvRN9C%2FUxfoba6Fvx9eMQ%2B8%2FrH7krjTWFMXB0zB8L%2Fg0m3tStfu%2BbtmOwjDTzgysf%2B48QJvqs%2BFOFqxSJq7FYZgG&webInteractiveContentId=412216133822&portalId=25734893) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLq3ExJ1vvVZLqTYQKUKszzECna8UfNJMyWftlkE5q0N7yQ5muraa43pMDOGoPsNz8F3s0s3iWPLTXB636a9l9ssA4ZYjuJMlTE6Nl0fQsAp596tvRN9C%2FUxfoba6Fvx9eMQ%2B8%2FrH7krjTWFMXB0zB8L%2Fg0m3tStfu%2BbtmOwjDTzgysf%2B48QJvqs%2BFOFqxSJq7FYZgG&webInteractiveContentId=412216133822&portalId=25734893) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic) [Home](https://simsendiagnostics.com/) / [Company](https://simsendiagnostics.com/company-about) / [News](https://simsendiagnostics.com/news) / Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial [← Back to all news](https://simsendiagnostics.com/news) Corporate Customer # Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial By **Simsen** November 17, 2025, 3:30:46 PM GMT+01:00 1 min read ![](https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%20laboratory%20setting%20filled%20with%20advanced%20equipment%20and%20technology.jpeg)   **Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial** Simsen Diagnostics, a leader in ultra-sensitive analysis of nucleic acids, today announced a collaboration with One-carbon Therapeutics, a Swedish pharmaceutical company, for their groundbreaking [ODIN trial.](https://clinicaltrials.gov/study/NCT07151040?term=NCT07151040&rank=1#study-overview) This first-in-human, first-in-class Phase 1/2 clinical trial will evaluate TH9619, a novel MTHFD1/2 inhibitor, in patients with selected solid cancers. One-carbon selected Simsen Diagnostics after a thorough vendor evaluation process. Simsen will deploy its highly sensitive Simsen® Personal solution, powered by the proprietary SiMSen-Seq platform, to monitor circulating tumor DNA (ctDNA) throughout the trial. Simsen® Personal allows for personalized tracking of tumor-specific genetic variations over time using simple blood draws. This approach offers the potential to detect minimal residual disease, monitor treatment response, identify relapse earlier, and deepen the understanding of disease evolution. The primary objective of the ODIN trial is to determine the optimal dose regimen for TH9619 through dose escalation. The precise and reliable data generated by Simsen® Personal will be instrumental in guiding this process and evaluating the therapeutic potential of TH9619. “We are thrilled to partner with One-carbon Therapeutics on this important clinical trial,” said Dr. Stefan Filges, Simsen’s CTO. “The ODIN trial represents a significant step forward in the development of innovative cancer treatments, and we are confident that our services will provide valuable insights to support One-carbon’s research.” This collaboration leverages the combined expertise and cutting-edge technologies of both Simsen Diagnostics and One-carbon Therapeutics, aiming to accelerate the development of more effective and personalized cancer therapies. **About Simsen Diagnostics:** Simsen Diagnostics is a Swedish precision diagnostics company, transforming minute traces of DNA into actionable answers for clinical challenges. From its base at AstraZeneca’s BioVentureHub in Gothenburg, Simsen delivers ultra-sensitive sequencing and AI-powered bioinformatics for oncology (ctDNA), enabling cancer clinics, pharmaceutical partners, and researchers to detect and act on signals previously undetectable. By combining high sensitivity, robust data security, and user-friendly solutions, Simsen Diagnostics is driving progress in cancer care, with the goal of providing clear molecular answers – from trace to truth. [https://simsendiagnostics.com/](https://simsendiagnostics.com/) **About One-carbon Therapeutics:** One-carbon Therapeutics AB is tackling the most difficult to treat cancers, inflammation and autoimmune diseases by targeting the disease specific one-carbon metabolism pathway, representing a novel way of attacking the DNA damage response (DDR). Co-founded in 2020 by the Helleday Laboratory, with over 20 years of experience in DNA damage response (DDR) biology, we are taking the previous success of discovering the synthetic lethal concept for the treatment of BRCA mutated cancer with PARP inhibitors to a new level; attacking difficult to treat cancers using synthetic lethality in the one-carbon pathway to target the DNA damage response for treatment of cancer and inflammation. [https://one-carbon.com](https://one-carbon.com/) **Contact:** Stefan Filges CTO, Simsen Diagnostics stefan@simsendiagnostics.com #### Share [mailto:?subject=Simsen+Diagnostics+Partners+with+One-carbon+Therapeutics+for+Groundbreaking+ODIN+Cancer+Trial&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial](mailto:?subject=Simsen+Diagnostics+Partners+with+One-carbon+Therapeutics+for+Groundbreaking+ODIN+Cancer+Trial&body=https%3A%2F%2Fsimsendiagnostics.com%2Fnews%2Fsimsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial) #### On this page ## More from Simsen ### [June 16, 2026, 3:23:28 PM GMT+02:00 · Corporate Closing the gap between cancer research and patients is partly a question of where the test runs](https://simsendiagnostics.com/news/momentum2026-pre-event) ### [December 17, 2025, 11:57:23 AM GMT+01:00 · Corporate From more treatment to smarter treatment: how tumour‑informed ctDNA monitoring can reduce harm and free capacity in cancer care](https://simsendiagnostics.com/news/from-more-treatment-to-smarter-treatment-how-tumour-informed-ctdna-monitoring-can-reduce-harm-and-free-capacity-in-nordic-cancer-care) ### [November 11, 2025, 12:03:55 PM GMT+01:00 · Corporate How Pharma Companies Can Leverage Simsen Diagnostic’s Tumour-Informed ctDNA Analysis to Transform Cancer Drug Trials](https://simsendiagnostics.com/news/how-pharma-companies-can-leverage-simsen-diagnostics-tumour-informed-ctdna-analysis-to-transform-cancer-drug-trials) Talk to us ## Running a trial or service that needs this kind of signal? Tell us about your study and your endpoints. A real scientist in CET/CEST will reply. [Request a conversation](https://simsendiagnostics.com/start-a-conversation) [Back to all news](https://simsendiagnostics.com/news) ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Simsen", "url" : "https://simsendiagnostics.com/news/author/simsen" }, "dateModified" : "2025-11-17T14:41:49.896Z", "datePublished" : "2025-11-17T14:30:46.000Z", "headline" : "Simsen Diagnostics Partners with One-carbon Therapeutics for Groundbreaking ODIN Cancer Trial", "image" : [ "https://simsendiagnostics.com/hubfs/AI-Generated%20Media/Images/The%20image%20depicts%20a%20modern%20laboratory%20setting%20filled%20with%20advanced%20equipment%20and%20technology.jpeg" ], "mainEntityOfPage" : { "@id" : "https://simsendiagnostics.com/news/simsen-diagnostics-partners-with-one-carbon-pharmaceuticals-for-groundbreaking-odin-cancer-trial", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://simsendiagnostics.com/hubfs/SD_logo%20medium-2.png" }, "name" : "Simsen Diagnostics AB" } } ```